Login
Clarity Pharmaceuticals cements record biotech IPO
KPMG Law has advised Clarity Pharmaceuticals on what’s being dubbed the largest clinical-stage biotech IPO in ASX history.
Emma Musgrave
Firm: KPMG Law (Clarity Pharmaceuticals).
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Clarity Pharmaceuticals has completed an IPO and officially listed on the ASX.
Value: $92 million for the IPO, approximately $360 million market capitalisation.
Area: Corporate.
Key players: The KPMG Law team was led by head of corporate and M&A David Morris, and was supported by director David Tink, solicitors Bree Taylor and Andrew Antoun and graduates Matthew Dean and Oscar Liu.
Deal significance: Clarity Pharmaceuticals is an Australian-based clinical stage radiopharmaceutical company that is developing next-generation products to address the growing need for the use of radiopharmaceuticals in the diagnosis and therapy of cancers in children and adults.
“We understand that the Clarity Pharmaceuticals IPO is the largest clinical stage biotech IPO ever completed on the ASX,” Mr Morris said.
“We’re delighted to have advised Clarity Pharmaceuticals on this significant transaction. It brings to the market a proudly Australian business with a goal of improving the treatment of children and adults with cancer around the world.
“We wish the directors and management of Clarity Pharmaceuticals every success in the company’s journey as an ASX-listed company and we look forward to seeing the company’s continued growth and contribution to the global oncology market.”
